Geon(TM) DB4426B WHITE UV 80A UV DK BLUE GELOY The more complete the information, the more accurate the search result - e.g. a search that only includes the number "8700" or the word "RED" will yield very large results sets).

W/0 UV ACORN BROWN W/0 UV CHESTNUT The more complete the information, the more accurate the search result - e.g. a search that only includes the number "8700" or the word "RED" will yield very large results sets).

MYRTLE PC UV CADET PC UV The more complete the information, the more accurate the search result - e.g. a search that only includes the number "8700" or the word "RED" will yield very large results sets).

UV BRONZE LUSTRE V3 GRAY UV 223381CPUV The more complete the information, the more accurate the search result - e.g. a search that only includes the number "8700" or the word "RED" will yield very large results sets).

BLUE/GREY LID W/UV PP #2 ULTIMATE GREY UV 17-5104 The more complete the information, the more accurate the search result - e.g. a search that only includes the number "8700" or the word "RED" will yield very large results sets).

  • A reconciliation of each non‐GAAP financial measure with the most directly  comparable GAAP financial measure is attached to this presentation which is co pa ab e G a c a easu e s attac ed to t s p ese tat o c s posted on our website at www.polyone.com.  Page 3 Strategy and Execution Drive Results 90% $22 $24 PolyOne Stock Price 50% $18 $20 $22 S&P 500 (relative performance) 30% $12 $14 $16 S&P 500 (relative performance) ‐10% 10% $6 $8 $10 50% ‐30% $0 $2 $4 $ | ‐50%$0 2006 2007 2008 2009 2010 2011 2012 2013 Page 4 Four Pillar Strategy The World’s Premier Provider of SpecializedThe World s Premier Provider of Specialized  Polymer Materials, Services & Solutions Page 5 Spartech – Compelling Strategic Rationale • Spartech expands PolyOne’s specialty portfolio with adjacent  technologies in attractive end markets  Bolt on acquisition with opportunity for global expansion as only Bolt‐on acquisition with opportunity for global expansion, as only  6% of Spartech’s revenues are outside of North America • PolyOne has a proven management team with a track record of  transformational success • Preliminary synergy estimated at $65 million run rate by end of  3year 3  Significant opportunity to expand profitability by leveraging  PolyOne’s four pillar strategy • Substantial potential share price appreciation for all  shareholders f f ll / $ Accretive to EPS in first full year post‐acquisition / $0.50 once  synergies realized Page 6 Mix Shift Highlights Specialty Transformation  Old  PolyOne Transformation 100% 2015 Target 80% In co m e*   65 – 75%40% 60% f O pe ra tin g  34% 43% 45% 65  75% 20%  o f 2%0% 2005 2008 2010 2012 2015 Specialty OI $5M   $46M                        $87M                       $114M                     Target *Operating Income excludes corporate charges and special items JV's PP&S Distribution Specialty Page 7 Proof of Performance 2007 2012 2015 “Where we were” “Where we are” “Where we Where we were Where we are expect to be" 1)  Operating Income % Specialty 3.2% 9.1% 12 – 16% PP&S 6.1% 9.0% 9 – 12% Distribution 3.0% 6.4% 6 – 7.5% 2)  Specialty Platform sss% of Operating Income 20% 45% 65 – 75% 3) ROIC* ( ft t ) 7% 11% 15%3) ROIC* (after‐tax) 7% 11% 15% 4)  Adjusted EPS Growth** N/A 4 yr CAGR = 55% Double Digit  Expansion *ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period **4 yr EPS CAGR calculated using 2012 adjusted EPS vs 2008 adjusted EPS Page 8 Proof of Performance Spartech Opportunity Intermediate  PolyOne Spartech Opportunity 2006 2012 Today Goal “Where we were” “Where we are” “Where  Spartech is”* “Where we can go”were are Spartech is can go Specialty Operating Margin 1.5% 9.1% 2.2% 8.0% – 10.0%  Margin Page 9 *Pro Forma results include Spartech corporate allocations for FY12 ended November 3, 2012 PolyOne 14% Latin America 3% Distribution 2012 Revenues: $4.2 Billion* 2012 Revenues: $4.2 Billion* United States 14% 5% PP&S 20%Specialty 57% Building & HealthCare 1.02 1.20 $1.20 $1.40 ha re End Markets* EPS Growth Construction 14% 17% Industrial 9% 0.27 0 21 0.79 $0.40 $0.60 $0.80 $1.00 Ad ju st ed  E ar ni ng s P er  S Electrical & 0.12 0.21 0.13 $0.00 $0.20 2006 2007 2008 2009 2010 2011 2012 Page 10 * Pro Forma includes FY2012 results for Spartech (11/03/12 YE) and Glasforms Specialty U it d 2012 Revenues: $2.4 Billion* Solutions United States 59% 9% Latin America Building & C t ti HealthCare   o f S al es 12-16% End Markets* Expanding Profits Construction Electrical & Industrial 15% 1.5% 3.2% 4.3% 5.3% 8.4% 9.1% O pe ra tin g  In co m e  Page 11 2006 2007 2008 2009 2010 2011 2012 2015 O Target* Pro Forma includes FY2012 results for Spartech (11/03/12 YE) and Glasforms Designed Structures and Solutions United States 2012 Revenues: $0.85 Billion* Solutions 84% Latin America 4% Building & Construction Sign & Advertising 3% Recreation & Leisure Pool & Spa 1% Distribution & Thermoform 2% Operating Income % of Sales 2012 Revenue by Industry Segment* Expanding Profits** Electrical & Electronics 23%Industrial 3% 2.2% 8 ‐ 10% 1% HealthCare 2012 2015 Target  Page 12 *Pro Forma includes FY2012 results for Spartech (11/03/12 YE) **Pro Forma results include Spartech corporate allocations for FY12 Positioned for Earnings Growth 2015 Target Rev: $5B Adj.  EPS: $2.50 Assumptions • High single digit organic  revenue CAGR • Operating margins in mid range  of 2015 targets • No global recession• No global recession • No investment in incremental  PP&S capacity • Completion of 2‐3 midsize  accretive acquisitions • No divestitures  • Housing starts at 85% of 50 year  norm by 2015 R i f t bl b l 3X N t 2012 $ • Remain comfortably below 3X Net  Debt / EBITDA Page 13 Rev: $3.0B Adj. 

Versaflex HC - Syringe Plunger - English SYRINGE MANUFACTURER D I S P O S A B L E S Y R I N G E P L U N G E R • USP VI and ISO 10993-4,5 compliant • Sterilize by gamma & EtO • Long-term sealing performance • Low coefficient of friction (COF) • Consistent performance across barrel sizes • Provided a formulated solution that met rigorous medical application requirements • Improved global supply continuity • Increased process efficiency by replacing previous thermoset material with TPE Versaflex™ HC 2110-57B KEY REQUIREMENTS WHY AVIENT?

HEALTHCARE DEVICE OEM S U R G I C A L S T A P L E R H O U S I N G • Easy-to-mold, durable, and good aesthetics • Excellent disinfection performance and good chemical resistance • Compatible with high- and low-temperature sterilization • Delivered durable and aesthetically pleasing specialty polymer with the added benefit of processing flexibility without retooling • Passed physical, chemical and disinfection tests in different testing conditions which proved good tensile strength and chemical resistance • Achieved consistent molding shape and properties Trilliant™ HC Thermoplastics KEY REQUIREMENTS WHY AVIENT?

AEROSPACE INTERIORS OEM S E A T S P A C E R & A R M R E S T • Weight reduction to increase airliner fuel economy • Meet FAA safety requirements for FST compliance and 16G kinetic survivability • Agility to delivery solution within 8-month compressed product development timeline • Achieved 40% weight reduction generating $16,000 per year reduction in fuel costs • Optimized component designs for long fiber material and conducted FEA validation • Performed prototype molding and testing for load and impact specifications to expedite development Complēt™ Long Carbon Fiber PES Composite KEY REQUIREMENTS WHY AVIENT?

SYRINGE MANUFACTURING D I S P O S A B L E S Y R I N G E T I P C A P • Excellent sealing and resealing performance • No DEHP or natural rubber latex added during processing • Can be sterilized by EtO • Compliance with ISO 10993-4&5, USP Class VI Dynaflex™ Thermoplastic Elastomer KEY REQUIREMENTS WHY AVIENT?